LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces it is investigating claims against Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Dr. Reddy’s were false and misleading concerning the Company’s financial performance.
To join this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at firstname.lastname@example.org.
On November 6, 2015, the Company announced that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.